Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (DE:135A)
FRANKFURT:135A
SCYNEXIS (135A) Stock Price & Analysis
0 Followers
135A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.25 - €3.35
Previous Close€1.88
Volume0.00
Average Volume (3M)2.39K
Market Cap
€73.92M
Enterprise Value€8.33M
Total Cash (Recent Filing)$74.36M
Total Debt (Recent Filing)$2.92M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 12, 2024EPS Estimate
-€0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,779,796
10 Day Avg. Volume0
30 Day Avg. Volume2,387
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.80
Price to Sales (P/S)0.46
Price to Cash Flow (P/CF)1.50
P/FCF Ratio1.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.06
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
€7.12Price Target Upside277.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
SCYNEXIS News
Bulls Say, Bears Say
Bulls Say
Cash PositionThe company remains well-capitalized with a cash position to provide runway through 2025 and expects to resolve the hold within 2024.
Financial PerformanceScynexis reported revenue of $140.1M, with $139M associated with the licensing agreement with GlaxoSmithKline.
Product Approval And DesignationsScynexis gained FDA approval for Brexafemme (ibrexafungerp) for the treatment of vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (rVVC), as well as Qualified Infectious Disease Product and Fast Track designations in refractory infections.
Bears Say
Clinical Hold And RecallScynexis placed a temporary clinical hold and recalled Brexafemme tablets following a review by GSK of its manufacturing process that found a non-antibacterial beta-lactam drug substance is manufactured using equipment common to the manufacturing process for IBX.
Deal AmendmentGSK’s deal was amended, now worth less than $434 million, due to an adjustment of sales milestones following IBX’s manufacturing issues.
Study ImpactManufacturing delay and recall has put the MARIO study on hold, impacting timelines.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.51% Insiders
31.54% Mutual Funds
4.96% Other Institutional Investors
47.99% Public Companies and
Individual Investors
135A FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was €1.25 and its highest was €3.35 in the past 12 months.
What is SCYNEXIS’s market cap?
Currently, no data Available
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Aug 12, 2024 which is in 20 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on May 09, 2024. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.169 by €0.178.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -€0.14.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 37,779,797 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.169. Following the earnings report the stock price went down -1.662%.
Which hedge fund is a major shareholder of SCYNEXIS?
Among the largest hedge funds holding SCYNEXIS’s share is Scion Asset Management. It holds SCYNEXIS’s shares valued at N/A.
---
SCYNEXIS Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.12 (277.86% Upside)
€7.12 (277.86% Upside)
Blogger Sentiment
Bullish
DE:135A Sentiment 80%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.19%
12-Months-Change
Fundamentals
Return on Equity
458.59%
Trailing 12-Months
Asset Growth
68.22%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
---
135A Company Deck
---
135A Earnings Call
Q4 2023
0:00 / 0:00
---
135A Stock 12 Month Forecast
Average Price Target
€7.12
▲(277.86% Upside)
Technical Analysis
Best Analysts Covering 135A
1 Year
1 Year Success Rate
9/37 ratings generated profit
1 Year Average Return
-19.57%
reiterated a buy rating 2 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 24.32% of your transactions generating a profit, with an average return of -19.57% per trade.
---